Products in Development
Targeting multiple tumor types
The Novartis Oncology pipeline includes compounds in all phases of development, starting with preclinical studies in tumor cell line and animal models through large Phase III randomized trials.
A Pipeline That Spans All Phases
Click on the compound name below to learn more.
AUY922
Solid tumors
Dovitinibd
Solid tumors & Hemat. tumors
INC424f
Myelofibrosis
Everolimus
Gastric cancer, Lymphoma
LCL161
Solid tumors
Lucatumumabe
Hemat. tumors
Pasireotideg
Cushing's disease
Panobinostatc
Multiple Myeloma
MEK162b
Solid tumors
Panobinostatc
Hemat. tumors
Everolimus
ER+ & HER2+ Breast Cancer
Nilotinib
cKIT Melanoma
LFA102e
Solid tumors
LDK378
Solid tumors
All compounds or uses are investigational. Efficacy and safety have not been established. There is no guarantee that they will become commercially available.
2
3
4
5
6
a
b
c
d
e
f
g
h
*
Non-Transfusion-Dependent Thalassemia
Acute myeloid leukemia
Tuberous sclerosis complex and angiomyolipomas
Hepatocellular carcinoma
metastatic Renal Cell Carcinoma
INC280 (also known as INCB028060) is
licensed from Incyte Corp.
MEK162 (also known as ARRY-162) is
licensed from Array BioPharma Inc.
Also known as LBH589
Also known as TKI258
Subject to an agreement between Novartis Oncology and Xoma.
INC424, also known as INCB018424, is being developed collaboratively by Incyte and Novartis AG. Novartis AG has licensed the rights to INC424 outside the United States. Incyte maintains the rights within the United States.
Also known as SOM230
LEE011 was discovered in collaboration with Astex
Phase II trial conducted by Incyte (NCT00726232)
About Novartis Oncology
We are one of the premier companies providing you with the best oncology treatments available.
CAREERS
We are committed to building the smartest and most capable team in the industry.
OPM Newsletter
OPM Newsletters provide quarterly updates on the latest topics in health care reform, policy, reimbursement, and information for practice managers.
